Fig. 4.

Combination of K03861 and paclitaxel results in synergistic growth inhibition in TNBC cells with high-ACTL6A. a-c Soft agar assay, colony formation assay and MTT assay were performed in vehicle, K03861 (50 nM), PTX (100 nM) or combination of K03861 and PTX groups in ACTL6A overexpressing cells. Scale bars represent 200 μm. d Flow cytometric analysis of the indicated cells with different treatments. e SUM159PT cells with or without ACTL6A overexpressing were subcutaneously injected into mice (1 × 10⁶/injection, n = 6/group). One week after inoculation, the mice were intraperitoneally injected with K03861 (5 mg/kg, once a day for 5 consecutive days each week, for up to 7 weeks), PTX (10 mg/kg, once a day for 5 consecutive days each week, for up to 7 weeks), combination with two drugs or vehicle. f The tumor volumes in each group are shown. g IHC of Ki-67 staining showed in the indicated xenografts. Scale bars represent 50 μm. Data represent the means ± S.D. of three independent experiments. Two-tailed Student’s t test was used. *P < 0.05, **P < 0.01, ***P < 0.001